Advertisement

Advertisement

KROS Stock Latest News

Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks

RatingsBalanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks

Keros Therapeutics Advances Rinvatercept in ALS Collaboration

PremiumCompany Announcements

Keros Therapeutics Advances Rinvatercept in ALS Collaboration

2M ago

Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center

PremiumThe Fly

Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center

2M ago

Keros Therapeutics presents additional data from Phase 1 of rinvatercept

PremiumThe Fly

Keros Therapeutics presents additional data from Phase 1 of rinvatercept

2M ago

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

PremiumCompany Announcements

Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

2M ago

Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo

PremiumThe FlyKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo

2M ago

Keros Highlights Rinvatercept Strategy in Updated Investor Presentation

Company Announcements

Keros Highlights Rinvatercept Strategy in Updated Investor Presentation

2M ago

KROS Upcoming Earnings Report: What to Expect?

Pre-Earnings

KROS Upcoming Earnings Report: What to Expect?

2M ago

Keros Therapeutics Adds Veteran Finance Leader to Board

PremiumCompany Announcements

Keros Therapeutics Adds Veteran Finance Leader to Board

2M ago

Keros Therapeutics CEO to Present at Multiple Conferences

PremiumCompany Announcements

Keros Therapeutics CEO to Present at Multiple Conferences

2M ago

Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation

PremiumCompany Announcements

Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation

4M ago

Largest borrow rate increases among liquid names

PremiumThe Fly

Largest borrow rate increases among liquid names

5M ago

Keros Therapeutics price target raised to $19 from $18 at BofA

PremiumThe FlyKeros Therapeutics price target raised to $19 from $18 at BofA

5M ago

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

The Fly

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

6M ago

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

The Fly

Keros Therapeutics price target raised to $27 from $23 at Oppenheimer

6M ago

Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships

PremiumRatings

Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships

6M ago

Keros Therapeutics Reports Strong Revenue Growth

PremiumCompany Announcements

Keros Therapeutics Reports Strong Revenue Growth

6M ago

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

PremiumRatings

Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties

6M ago

Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating

PremiumRatings

Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating

6M ago

Keros Therapeutics reports Q3 EPS (18c), consensus (92c)

PremiumThe FlyKeros Therapeutics reports Q3 EPS (18c), consensus (92c)

6M ago

Keros Therapeutics to repurchase $194.4M of shares

The Fly

Keros Therapeutics to repurchase $194.4M of shares

7M ago

Keros Therapeutics Announces $375M Capital Return Program

Company Announcements

Keros Therapeutics Announces $375M Capital Return Program

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >